Aveanna Healthcare Holdings Inc.
AVAHAveanna Healthcare Holdings Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding.
The price is in a confirmed uptrend (13 weeks in) while the P/E sits at the 45th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +300.0% year on year. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Aveanna Healthcare Holdings Inc. trades at $14.3, in a confirmed uptrend and 13 weeks into that stage. That is +65.8% against its own 200-day average. It sits at 100% of a 52-week range of $6 to $14. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 14 straight weeks.
Today the stock is in a confirmed uptrend — week 13 of stage 2. At $14.3 it trades +65.8% versus its 200-day average and sits at 100% of its 52-week range ($6–$14).
Against the market, two honest reads. Cumulative: over the last 5.4 years the stock moved +22% while the S&P 500 moved +81% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 14 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Aveanna Healthcare Holdings Inc. trades at 11.6× P/E, mid-range by its own standards (45th percentile). Its long-run median P/E is 23.5×, measured across 1.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 11.6× is mid-range by its own standards (45th percentile), against a long-run median of 23.5× measured over 1.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Aveanna Healthcare Holdings Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | — | +8.5% | — | — |
| Stock price | +76.0% | +116.8% | +10.4% | — |
4-Factor Sector Score
54.4/100 — rank 7 of 30 in Medical Care Facilities · 58% evidence confidence
Aveanna Healthcare Holdings Inc. scores 54.4 out of 100 against the 30 companies it is compared with in Medical Care Facilities, ranking 7. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 11.7 + 11.8 + 11.4 + 19.5 = 54.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Aveanna Healthcare Holdings Inc. reported $0.7 B of revenue in the Apr 26 quarter, +16.1% year on year. Over 4 years it has compounded at 9.7% a year. The last full year, FY26, came in at $2.4 B. The last four reported quarters add to $2.5 B.
FY26 revenue came in at $2.4 B (+20.3% on the year), capping 4 years at 9.7% compound. The latest quarter (Apr 26) printed $0.7 B, +16.1% year on year.
Pace check: the last four quarters averaged +18.6% growth against the decade's 9.7% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +20.6% over the last 4 quarters against +14.6%/yr over the last 8 — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Aveanna Healthcare Holdings Inc.'s operating margin is 10.8% in the Apr 26 quarter, +1.9 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged −35.8% to 10.7%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 10.8%, +1.9 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −35.8%–10.7%, and FY26's 10.7% is the top of that band — a record year.
Why the margin moved: operating margin went +1.9 pp year on year while gross margin went +0.2 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Aveanna Healthcare Holdings Inc. earned $0.0 B of net profit in the Apr 26 quarter, +300.0% year on year. Full-year FY26 profit was $0.2 B. That is 6.2% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 4 of the last 12 reported quarters were loss-making.
Apr 26 profit was $0.0 B, +300.0% year on year. On the full year, FY26 printed $0.2 B (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Aveanna Healthcare Holdings Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY26 that was $0.1 B of operating cash against $0.2 B of profit. After $0.0 B of capital spending, $0.1 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY26: operating cash of $0.1 B against reported profit of $0.2 B, leaving free cash of $0.1 B after $0.0 B of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Aveanna Healthcare Holdings Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY26 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Aveanna Healthcare Holdings Inc. earns a ROE of 115% in FY26. That is up from a trough of −19% in FY22. Return on invested capital clears the cost of that capital by +6.1 percentage points, so growth here adds value rather than only size. The wiring behind it is 9.5% net margin on 1.21× asset turns.
FY26 ROE is 115%, recovered from a FY22 trough of −19% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 9.5% net margin × 1.21× asset turns × 10.05× balance-sheet leverage ≈ 115.5% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 18.6% − 12.5% = a +6.1 pp spread. The 12.5% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend
Aveanna Healthcare Holdings Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Aveanna Healthcare Holdings Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Aveanna Healthcare Holdings Inc. carries total debt of $1.5 B against shareholder equity of $0.2 B as of Apr 26, a debt-to-equity of 6.25. On the annual view that ratio went from 2.20 in FY22 to 7.55 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Apr 26: total debt of $1.5 B against shareholder equity of $0.2 B — a debt-to-equity of 6.25. On the annual view, debt-to-equity went from 2.20 (FY22) to 7.55 (FY26). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
5.3% of Aveanna Healthcare Holdings Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 1.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 5.3% of the float is sold short, and at typical trading volumes it would take about 1.5 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Aveanna Healthcare Holdings Inc.: the Z-score reads 1.55. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
🚨 Why it matters: a Z-score of 1.55 is inside the distress zone — the balance sheet is a real risk, not a detail.
The safety line in one sentence: the Z-score reads 1.55.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Tenet Healthcare CorporationTHC | 65.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 24.1/35 Revenue — · PAT — · OPM change 6.2 pp 45% evidence | 16.4/25 ROCE 5.8% · OPM 23.2% 76% evidence | 11.0/20 P/E 7.2× · PEG — 15% evidence | 13.7/20 RS sector -3.7% · RS bench 18.8% · 1Y 39.8%9 of 12 weeks ahead 100% evidence |
| Exact sum: 24.1 + 16.4 + 11 + 13.7 = 65.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Concentra Group Holdings Parent, Inc.CON | 62.0/100Mixed-positive evidence71% evidence | LEADER | 19.8/35 Revenue 15.5% · PAT 12.9% · OPM change 0.8 pp 83% evidence | 14.7/25 ROCE 3.8% · OPM 16.8% 76% evidence | 10.1/20 P/E 15.4× · PEG — 15% evidence | 17.4/20 RS sector 13.5% · RS bench 38% · 1Y 76%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 14.7 + 10.1 + 17.4 = 62 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Encompass Health CorporationEHC | 61.5/100Mixed-positive evidence81% evidence | BREAKING OUT | 20.8/35 Revenue 10.1% · PAT 21% · OPM change 0.7 pp 83% evidence | 15.8/25 ROCE 4.9% · OPM 19% 76% evidence | 14.0/20 P/E 16.1× · PEG 0.68 65% evidence | 10.9/20 RS sector -15.3% · RS bench 5.4% · 1Y -0.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 20.8 + 15.8 + 14 + 10.9 = 61.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Addus HomeCare CorporationADUS | 56.9/100Mixed-positive evidence81% evidence | BREAKING OUT | 21.2/35 Revenue 19.5% · PAT 26.6% · OPM change 0.4 pp 83% evidence | 12.3/25 ROCE 2.7% · OPM 9.4% 76% evidence | 13.4/20 P/E 17.3× · PEG 0.78 65% evidence | 10.0/20 RS sector -17.2% · RS bench 3% · 1Y 5.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 12.3 + 13.4 + 10 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Nutex Health Inc.NUTX | 55.9/100Mixed-positive evidence75% evidence | LEADER | 17.5/35 Revenue 40.8% · PAT 31.3% · OPM change -0.6 pp 83% evidence | 15.9/25 ROCE 12.1% · OPM 37.5% 76% evidence | 6.8/20 P/E 6.9× · PEG 2.9 65% evidence | 15.7/20 RS sector 20.7% · RS bench 47.8% · 1Y 126.1%11 of 12 weeks ahead 70% evidence |
| Exact sum: 17.5 + 15.9 + 6.8 + 15.7 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6LifeStance Health Group, Inc.LFST | 55.4/100Mixed-positive evidence64% evidence | LEADER | 22.4/35 Revenue 16.4% · PAT — · OPM change 5 pp 62% evidence | 5.8/25 ROCE 1.2% · OPM 5.5% 76% evidence | 8.5/20 P/E 106.2× · PEG — 15% evidence | 18.7/20 RS sector 25.5% · RS bench 51.5% · 1Y 144.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.4 + 5.8 + 8.5 + 18.7 = 55.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Aveanna Healthcare Holdings Inc.this pageAVAH | 54.4/100Thin evidence · provisional58% evidence | LEADER | 11.7/35 Revenue — · PAT — · OPM change -2.9 pp 45% evidence | 11.8/25 ROCE 4.8% · OPM 10.7% 76% evidence | 11.4/20 P/E 5.4× · PEG — 15% evidence | 19.5/20 RS sector 24.4% · RS bench 53.1% · 1Y 76%12 of 12 weeks ahead 100% evidence |
| Exact sum: 11.7 + 11.8 + 11.4 + 19.5 = 54.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8PACS Group, Inc.PACS | 53.7/100Thin evidence · provisional56% evidence | LEADER | 22.2/35 Revenue — · PAT — · OPM change 4.7 pp 39% evidence | 13.3/25 ROCE 5.2% · OPM 8.5% 76% evidence | 9.1/20 P/E 31.5× · PEG — 15% evidence | 9.1/20 RS sector -2.3% · RS bench 18.1% · 1Y 256.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 13.3 + 9.1 + 9.1 = 53.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Chemed CorporationCHE | 53.4/100Thin evidence · provisional58% evidence | BREAKING OUT | 18.2/35 Revenue — · PAT — · OPM change -1.7 pp 45% evidence | 15.6/25 ROCE 6.6% · OPM 12.9% 76% evidence | 9.3/20 P/E 23.4× · PEG — 15% evidence | 10.3/20 RS sector -13.8% · RS bench 6.4% · 1Y 12.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 15.6 + 9.3 + 10.3 = 53.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Fresenius Medical Care AGFMS | 52.9/100Mixed-positive evidence81% evidence | ASLEEP | 21.9/35 Revenue -0.7% · PAT 43.7% · OPM change 1.5 pp 83% evidence | 11.3/25 ROCE 2.1% · OPM 11.7% 76% evidence | 15.7/20 P/E 11.9× · PEG 0.22 65% evidence | 4.0/20 RS sector -27% · RS bench -9% · 1Y -9.2%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 11.3 + 15.7 + 4 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Guardian Pharmacy Services, Inc.GRDN | 51.0/100Mixed-positive evidence64% evidence | TURNING | 17.6/35 Revenue 13.6% · PAT — · OPM change 1.4 pp 62% evidence | 12.3/25 ROCE 7.8% · OPM 5.3% 76% evidence | 8.7/20 P/E 45.4× · PEG — 15% evidence | 12.4/20 RS sector 3% · RS bench 25.9% · 1Y 82.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 12.3 + 8.7 + 12.4 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12HCA Healthcare, Inc.HCA | 50.9/100Mixed-positive evidence85% evidence | BREAKING OUT | 14.6/35 Revenue 7.3% · PAT 14.1% · OPM change -0.7 pp 95% evidence | 15.6/25 ROCE 6.9% · OPM 15.2% 76% evidence | 15.1/20 P/E 13.1× · PEG 0.51 65% evidence | 5.6/20 RS sector -28.6% · RS bench -10.7% · 1Y 7%4 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 15.6 + 15.1 + 5.6 = 50.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 13Healthcare Services Group, Inc.HCSG | 50.8/100Thin evidence · provisional52% evidence | FADING | 23.0/35 Revenue — · PAT — · OPM change 2.2 pp 45% evidence | 10.7/25 ROCE 3.6% · OPM 7.3% 76% evidence | 10.3/20 P/E 14.3× · PEG — 15% evidence | 6.8/20 RS sector -17.5% · RS bench 1.4% · 1Y 38.3%6 of 12 weeks ahead 70% evidence |
| Exact sum: 23 + 10.7 + 10.3 + 6.8 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14National HealthCare CorporationNHC | 48.7/100Mixed-negative evidence81% evidence | LEADER | 16.9/35 Revenue 10.3% · PAT 16.7% · OPM change 0.2 pp 83% evidence | 10.2/25 ROCE 2.5% · OPM 8.4% 76% evidence | 9.8/20 P/E 20.3× · PEG 1.48 65% evidence | 11.8/20 RS sector 2.7% · RS bench 24.7% · 1Y 92.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 10.2 + 9.8 + 11.8 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Universal Health Services, Inc.UHS | 48.1/100Thin evidence · provisional58% evidence | BREAKING OUT | 16.7/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 14.0/25 ROCE 4.1% · OPM 11.2% 76% evidence | 11.3/20 P/E 6.1× · PEG — 15% evidence | 6.1/20 RS sector -29.4% · RS bench -11.2% · 1Y -3.9%5 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 14 + 11.3 + 6.1 = 48.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16agilon health, inc.AGL | 47.6/100Mixed-negative evidence61% evidence | FADING | 18.8/35 Revenue -2.8% · PAT — · OPM change 1.7 pp 62% evidence | 4.8/25 ROCE 1% · OPM 0.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.0/20 RS sector 54% · RS bench 76.9% · 1Y 209.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 4.8 + 10 + 14 = 47.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17The Pennant Group, Inc.PNTG | 46.7/100Mixed-negative evidence75% evidence | LEADER | 20.3/35 Revenue 36.6% · PAT 20.7% · OPM change 0.1 pp 83% evidence | 9.2/25 ROCE 2.3% · OPM 6.1% 76% evidence | 4.0/20 P/E 35.9× · PEG 3.03 65% evidence | 13.2/20 RS sector 1.7% · RS bench 24.3% · 1Y 76.1%11 of 12 weeks ahead 70% evidence |
| Exact sum: 20.3 + 9.2 + 4 + 13.2 = 46.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18The Ensign Group, Inc.ENSG | 45.9/100Thin evidence · provisional58% evidence | TURNING | 18.1/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 12.2/25 ROCE 2.7% · OPM 9% 76% evidence | 9.2/20 P/E 25.1× · PEG — 15% evidence | 6.4/20 RS sector -26.6% · RS bench -8.6% · 1Y 8.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 12.2 + 9.2 + 6.4 = 45.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19DaVita Inc.DVA | 45.5/100Mixed-negative evidence81% evidence | ASLEEP | 16.1/35 Revenue 6.7% · PAT -6.9% · OPM change 0.5 pp 83% evidence | 13.7/25 ROCE 3.3% · OPM 14.1% 76% evidence | 8.2/20 P/E 14.3× · PEG 2.08 65% evidence | 7.5/20 RS sector -5.3% · RS bench 14.9% · 1Y 48.9%5 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 13.7 + 8.2 + 7.5 = 45.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Pediatrix Medical Group, Inc.MD | 45.3/100Mixed-negative evidence74% evidence | LEADER | 17.7/35 Revenue -2.2% · PAT — · OPM change 1.7 pp 62% evidence | 10.1/25 ROCE 2.5% · OPM 8.7% 76% evidence | 10.0/20 P/E 10.4× · PEG 1.7 65% evidence | 7.5/20 RS sector -10.7% · RS bench 9.7% · 1Y 60.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 10.1 + 10 + 7.5 = 45.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Option Care Health, Inc.OPCH | 43.5/100Thin evidence · provisional58% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change -0.5 pp 45% evidence | 11.3/25 ROCE 3.3% · OPM 5.4% 76% evidence | 9.9/20 P/E 15.8× · PEG — 15% evidence | 5.0/20 RS sector -33.3% · RS bench -16.1% · 1Y -13.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 11.3 + 9.9 + 5 = 43.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Acadia Healthcare Company, Inc.ACHC | 42.8/100Thin evidence · provisional58% evidence | LEADER | 15.1/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 7.5/25 ROCE 1.1% · OPM 5.8% 76% evidence | 9.5/20 P/E 21.2× · PEG — 15% evidence | 10.7/20 RS sector -5.6% · RS bench 14.9% · 1Y 27.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 7.5 + 9.5 + 10.7 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Select Medical Holdings CorporationSEM | 40.3/100Mixed-negative evidence75% evidence | 11.0/35 Revenue 5.8% · PAT -20% · OPM change -1.4 pp 83% evidence | 9.8/25 ROCE 2% · OPM 6.9% 76% evidence | 12.9/20 P/E 15.4× · PEG 0.93 65% evidence | 6.6/20 RS sector -23% · RS bench 1.5% · 1Y 9%0 of 1 week ahead to 2026-07-02 70% evidence | |
| Exact sum: 11 + 9.8 + 12.9 + 6.6 = 40.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Ardent Health, Inc.ARDT | 40.2/100Mixed-negative evidence65% evidence | BREAKING OUT | 14.5/35 Revenue 6.7% · PAT -26.8% · OPM change 0.6 pp 83% evidence | 8.8/25 ROCE 1.9% · OPM 5.1% 76% evidence | 10.9/20 P/E 9× · PEG — 15% evidence | 6.0/20 RS sector -21.3% · RS bench -1.8% · 1Y -16.4%8 of 12 weeks ahead 70% evidence |
| Exact sum: 14.5 + 8.8 + 10.9 + 6 = 40.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Astrana Health, Inc.ASTH | 39.7/100Mixed-negative evidence81% evidence | ASLEEP | 14.5/35 Revenue 56.8% · PAT -20.5% · OPM change -0.3 pp 83% evidence | 7.4/25 ROCE 2.2% · OPM 3% 76% evidence | 10.5/20 P/E 40.2× · PEG 1.17 65% evidence | 7.3/20 RS sector -6.8% · RS bench 13.6% · 1Y 35.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 7.4 + 10.5 + 7.3 = 39.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26InnovAge Holding Corp.INNV | 38.1/100Thin evidence · provisional58% evidence | LEADER | 10.8/35 Revenue 14.2% · PAT — · OPM change -6.8 pp 62% evidence | 3.6/25 ROCE -8.8% · OPM -11.5% 76% evidence | 8.6/20 P/E 103.8× · PEG — 15% evidence | 15.1/20 RS sector 8.9% · RS bench 31.1% · 1Y 134.3%12 of 12 weeks ahead 70% evidence |
| Exact sum: 10.8 + 3.6 + 8.6 + 15.1 = 38.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Sonida Senior Living, Inc.SNDA | 36.0/100Mixed-negative evidence64% evidence | BREAKING OUT | 13.0/35 Revenue 25.5% · PAT — · OPM change -20.5 pp 62% evidence | 3.8/25 ROCE -1.9% · OPM -23.6% 76% evidence | 11.5/20 P/E 1.9× · PEG — 15% evidence | 7.7/20 RS sector -12.4% · RS bench 7.5% · 1Y 46.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 3.8 + 11.5 + 7.7 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Surgery Partners, Inc.SGRY | 35.1/100Mixed-negative evidence61% evidence | ASLEEP | 14.2/35 Revenue 5.4% · PAT — · OPM change 0.1 pp 62% evidence | 7.2/25 ROCE 0.9% · OPM 8.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.7/20 RS sector -33.9% · RS bench -17% · 1Y -35.6%5 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 7.2 + 10 + 3.7 = 35.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Brookdale Senior Living Inc.BKD | 33.5/100Adverse evidence61% evidence | ASLEEP | 17.3/35 Revenue -0.4% · PAT — · OPM change 3.2 pp 62% evidence | 5.0/25 ROCE 0.9% · OPM 6.8% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.2/20 RS sector -29.3% · RS bench -13.2% · 1Y 47.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 5 + 10 + 1.2 = 33.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30COMPASS Pathways plcCMPS | 48.2/100Thin evidence · provisional47% evidence | LEADER | 20.0/35 Revenue — · PAT — · OPM change — 33% evidence | 5.0/25 ROCE -12.9% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.2/20 RS sector 23.6% · RS bench 48.2% · 1Y 181.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 5 + 10 + 13.2 = 48.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Aveanna Healthcare Holdings Inc.'s stock price today?
Aveanna Healthcare Holdings Inc. trades at $14.3, +76.0% over the past year. The company is valued at $3.0 B. The stock sits at the very top of its 52-week range ($6–$14), +65.8% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 13 weeks in. — as of 17 September 2026.
What were Aveanna Healthcare Holdings Inc.'s latest quarterly results?
Aveanna Healthcare Holdings Inc. reported revenue of $0.7 B and net profit of $0.0 B for the Apr 26 quarter. Revenue rose 16.1% and profit rose 300.0% year on year. Earnings per share were $0.19. The operating margin was 10.8%, 1.9 pp higher than a year earlier. — as of 17 September 2026.
What is Aveanna Healthcare Holdings Inc.'s revenue?
Aveanna Healthcare Holdings Inc. reported revenue of $0.7 B in the Apr 26 quarter, +16.1% year on year. For the full FY26 fiscal year, revenue was $2.4 B (+20.3%). Over the last 4 years revenue compounded at 9.7% a year. — as of 17 September 2026.
What is Aveanna Healthcare Holdings Inc.'s profit?
Aveanna Healthcare Holdings Inc. earned $0.0 B of net profit in the Apr 26 quarter, +300.0% year on year. Full-year FY26 profit was $0.2 B. The operating margin ran 10.8% in the latest quarter. — as of 17 September 2026.
What is Aveanna Healthcare Holdings Inc.'s market cap?
Aveanna Healthcare Holdings Inc.'s market capitalisation is $3.0 B at a stock price of $14.3. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is Aveanna Healthcare Holdings Inc.'s P/E ratio?
Aveanna Healthcare Holdings Inc. trades at a P/E of 11.6×, at the 45th percentile of its own 1-year range, against a long-run median of 23.5×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does Aveanna Healthcare Holdings Inc. pay a dividend?
No — Aveanna Healthcare Holdings Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.
Is Aveanna Healthcare Holdings Inc. overvalued?
On its own history, Aveanna Healthcare Holdings Inc. looks mid-range: its P/E of 11.6× sits at the 45th percentile of its 1-year range (long-run median 23.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 17 September 2026.
Is Aveanna Healthcare Holdings Inc. growing?
Yes — Aveanna Healthcare Holdings Inc. is growing: latest-quarter revenue +16.1% year on year, profit +300.0%, and the margin +1.9 pp at 10.8%. The earnings engine currently reads: improving — as of 17 September 2026.
How is Aveanna Healthcare Holdings Inc. performing?
Aveanna Healthcare Holdings Inc. is in a confirmed uptrend, 13 weeks in. Its latest quarter's revenue rose 16.1% and profit rose 300.0% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 14 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
Is Aveanna Healthcare Holdings Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 13 of stage 2), trading +65.8% versus its 200-day average and at the very top of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Aveanna Healthcare Holdings Inc. beating the market?
On recent form, yes — Aveanna Healthcare Holdings Inc. has been ahead of the S&P 500 on a trailing-13-week view for 14 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5.4 years the stock moved +22% against the S&P 500's +81% — behind the index over the full window. — as of 17 September 2026.
Will Aveanna Healthcare Holdings Inc.'s stock price go up?
This page publishes no price forecast for Aveanna Healthcare Holdings Inc. What it measures instead: the stock price is $14.3, the price is in a confirmed uptrend 13 weeks in. Its P/E of 11.6× sits at the 45th percentile of its own 1-year range. — as of 17 September 2026.
Is the market betting against Aveanna Healthcare Holdings Inc.?
Somewhat — short interest is 5.3% of Aveanna Healthcare Holdings Inc.'s tradable float, about 1.5 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Aveanna Healthcare Holdings Inc. have too much debt?
It carries real leverage — Aveanna Healthcare Holdings Inc.'s debt-to-equity is 5.23. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is Aveanna Healthcare Holdings Inc.'s capex?
Aveanna Healthcare Holdings Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was $0.0 B. — as of 17 September 2026.
What is Aveanna Healthcare Holdings Inc.'s cash flow?
Aveanna Healthcare Holdings Inc. generated $0.1 B of operating cash flow in FY26 and $0.1 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.2 B, so operating cash ran behind profit. — as of 17 September 2026.
How financially safe is Aveanna Healthcare Holdings Inc.?
On the balance sheet, the Z-score reads 1.55 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is inside the danger band — a real balance-sheet risk. — as of 17 September 2026.
Where is Aveanna Healthcare Holdings Inc. in its business cycle?
Aveanna Healthcare Holdings Inc.'s FY26 operating margin was 10.7%, against a 5-year band of −35.8%–10.7%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 10.8%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Aveanna Healthcare Holdings Inc. story?
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Aveanna Healthcare Holdings Inc. a stock worth studying right now?
This is not investment advice. The machine read: Aveanna Healthcare Holdings Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!